UCB (EQUASYM worldwide rights) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

UCB (EQUASYM worldwide rights) General Information

Description

Portfolio of pharmaceutical rights and patents. The portfolio entails worldwide rights to the instant-release and extended-release versions of Equasym outside the United States, Canada and Barbados. Equasym IR and XL are used for the treatment of attention deficit hyperactivity disorder (ADD).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Brussels
  • Belgium
Primary Industry
Buildings and Property
Acquirer
Shire
Corporate Office
  • Brussels
  • Belgium

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

UCB (EQUASYM worldwide rights) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore UCB (EQUASYM worldwide rights)‘s full profile, request access.

Request a free trial

UCB (EQUASYM worldwide rights) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore UCB (EQUASYM worldwide rights)‘s full profile, request access.

Request a free trial

UCB (EQUASYM worldwide rights) FAQs

  • Where is UCB (EQUASYM worldwide rights) headquartered?

    UCB (EQUASYM worldwide rights) is headquartered in Brussels, Belgium.

  • What industry is UCB (EQUASYM worldwide rights) in?

    UCB (EQUASYM worldwide rights)’s primary industry is Buildings and Property.

  • Is UCB (EQUASYM worldwide rights) a private or public company?

    UCB (EQUASYM worldwide rights) is a Private company.

  • What is the current valuation of UCB (EQUASYM worldwide rights)?

    The current valuation of UCB (EQUASYM worldwide rights) is .

  • What is UCB (EQUASYM worldwide rights)’s current revenue?

    The current revenue for UCB (EQUASYM worldwide rights) is .

  • Who are UCB (EQUASYM worldwide rights)’s investors?

    UCB has invested in UCB (EQUASYM worldwide rights).

  • When was UCB (EQUASYM worldwide rights) acquired?

    UCB (EQUASYM worldwide rights) was acquired on 20-Feb-2009.

  • Who acquired UCB (EQUASYM worldwide rights)?

    UCB (EQUASYM worldwide rights) was acquired by Shire.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »